绘制心房动驱动器的地图
1The Department of Cardiovascular Medicine, Shin-Yurigaoka General Hospital, 215-0026 Kawasaki, Japan.
Reviews in cardiovascular medicine
|July 30, 2024
概括
肺静脉隔离有效治疗心房动 (AF). 然而,对于持久性AF,通过先进的映射来识别和准AF驱动器对于开发有效的废除策略至关重要.
科学领域:
- 电子生理学 电子生理学
- 心脏病学 心脏病学
- 医疗技术 医疗技术 医学技术
背景情况:
- 肺静脉开始心房动 (AF).
- 肺静脉隔离 (PVI) 对于偏激性AF是有效的,但对于非偏激性AF则不那么有效.
- 了解AF维护机制对于改进的切除策略至关重要.
研究的目的:
- 审查当前关于心房动 (AF) 驱动因素的知识.
- 为识别AF驱动器提供了对映射方法的全面概述.
- 为开发超越PVI的先进废弃策略提供信息.
主要方法:
- 审查关于AF机制和映射技术的现有文献.
- 分析了在动物模型和人类中确定AF的焦点或旋转驱动因素的研究.
- 对AF驾驶员识别指导导导管切除新技术的评估.
主要成果:
- 在AF中已经确定了焦点或旋转驱动器.
- 先进的绘图技术正在出现,以确定这些驱动因素.
- 这些技术作为导管切除程序的指南.
结论:
- 目前的PVI策略对于非发热性AF是不够的.
- 识别和准AF驱动器对于治疗持久性AF至关重要.
- 先进的绘图技术对于指导新的废弃策略至关重要.
相关概念视频
Disturbances in Heart Rhythm
927
Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
927
Mechanism of Cardiac Arrhythmias
909
Arrhythmias are irregular heart rhythms occurring when the heart's electrical impulses become abnormal. These disturbances can lead to various symptoms, depending on their severity and the underlying cause. Some common factors contributing to arrhythmias include hypoxia, ischemia, electrolyte imbalances, excessive catecholamine exposure, drug toxicity, and muscle overstretching. Arrhythmias can be classified into two main types based on the rate and site of origin of abnormal heart rhythms.
909
Anticoagulant Drugs: Low-Molecular-Weight Heparins
659
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
659
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
952
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
952
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
727
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
727
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
413
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
413


